A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy

European Journal of Cancer

Volumn 32, Issue 5, 1996, Pages 807-813

  Audhuy, B ^a   Cappelaere, P ^b   Martin, M ^c   Cervantes, A ^d   Fabbro, M ^e   Riviere A ^f   Khayat, D ^g   Bleiberg, H ^h   Faraldi, M ⁱ   Claverie, N ^j  

^a Pasteur Hospital   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e CENTRE VAL D AURELLE   (France)

^f Cancer Institute   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h JULES BORDET INSTITUTE   (Belgium)

ⁱ Hopital du Hasenrain CH de Mulhouse   (France)

^j SANOFI   (France)

more..

Author keywords

5 ht3 receptor antagonist; Anti emetic; Cisplatin; Clinical trial; Dolasetron; Emesis; Granisetron; Nausea; Serotonin

Indexed keywords

CISPLATIN; DOLASETRON MESILATE; GRANISETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOUBLE-BLIND METHOD; FEMALE; GRANISETRON; HUMANS; INDOLES; MALE; MIDDLE AGED; NAUSEA; QUINOLIZINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 8944260906     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00025-1     Document Type: Article

References (34)

1. Cooper S, Georgiou V. The impact of cytotoxic chemotherapy -perspectives from patients, specialists and nurses. Eur J Cancer 1992, 28A (Suppl. 1), S36-S38.
2. Lazlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983, 25 (Suppl. 1), 1-7.
3. Hesketh PJ. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991, 83, 613-620.
4. Gralla RJ. Current issues in the management of nausea and vomiting. Ann Oncol 1993, 4 (Suppl. 3), S3-S7.
5. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991, 42, 551-568.
6. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993, 329, 1790-1796.
7. Marty M, Fouillart P, School S, et al. Comparison of the 5-hydroxytryptamine-3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990, 322, 816-821.
8. Sledge GW Jr, Einhorn L, Nagy C, House K. Phase III double- blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992, 70, 2524-2528.
9. Allen JC, Gralla R, Reilly L, Kellick M, Young C. Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 1985, 3, 1136-1141.
10. Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989, 7, 1137-1141.
11. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 1992, 219, 9-13.
12. Galvan M, Gittos MW, Fatmi M. Dolasetron mesylate. Drugs Future 1993, 18, 506-509.
13. 3 receptors. Drug Dev Res 1993, 28, 87-93.
14. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992, 13, 693-701.
15. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 1994, 17, 97-102.
16. Hesketh PJ, Gandara DR, Hesketh AM, et al. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer (in press).
17. 3-receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 1993, 4, 481-484.
18. Kris MG, Grunberg SM, Gralla RJ, et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994, 12, 1045-1049.
19. Merrouche Y, Catimel G, Rebattu P, et al. A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Ann Oncol 1994, 5, 549-551.
20. Harman GS, Omura GA, Ryan K, Hainsworth JD, Cramer MB, Hahne WF. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol (in press).
21. Yeilding A, Bertoli L, Eisenberg P, et al. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol (in press).
22. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994, 74, 1945-1952.
23. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994, 12, 2204-2210.
24. Perez EA, Gandara DR. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced ernesis. Semin Oncol 1994, 21 (Suppl. 5), 15-21.
25. Plosker GL, Goa KL. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 1991, 42, 805-824.
26. Peace KM. Statistical Issues in Drug Research and Development. New York, Marcel Dekker Inc, 1990.
27. Navari R, Hesketh P, Grote T, et al. A double-blind, randomized, comparative IV study of single dose dolasetron vs ondansetron in preventing cisplatin-related emesis. Proc Am Soc Clin Oncol 1995, 14, 522.
28. Chevallier B, Cappelaere P, Splinter T, et al. Double-blind, randomized, comparative study of dolasetron (Dol) vs metoclopramide (MTC) in cisplatin-treated patients. Support Care Cancer 1995, 3, 336.
29. De Mulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Int Med 1990, 113, 834-840.
30. Markham A, Sorkin EM. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993, 45, 931-952.
31. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy: a randomized study. Eur J Cancer 1993, 29A, 1669-1672.
32. Kasimis B, Tapazoglou E, Schulman P, et al. A double-blind, randomized study of two different dose regimens of intravenous (IV) Dolasetron (DOL) in patients (PTS) receiving high dose cisplatin (CDDP) chemotherapy. Proc Am Soc Clin Oncol 1994, 13, 446.
33. Riviere A. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994, 69, 967-971.
34. Watanabe H, Hasegawa A, Shinozaki T, Arita S, Chigira M. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995, 35, 278-282.